Milne D, Hyatt A, Billett A, et al. Understanding the impact of immunotherapy side effects on quality of life of patients with stage IV melanoma not on clinical trial: ‘Real world’ data to inform supportive care interventions. SMR2017, abstract P05-3.
BO-112 plus pembrolizumab bij anti-PD-1-resistent gevorderd melanoom
aug 2025 | Dermato-oncologie, Immuuntherapie